Medications

Nasal spray approved for treating suicidal people

Johnson & Johnson's Spravato has been approved as the first antidepressant for actively suicidal people, as doctors are becoming increasingly concerned about COVID-19's effect on the mental health of Americans.

Psychology & Psychiatry

Hospital study examines the cost-effectiveness of esketamine

A paper authored by researchers from McLean Hospital has determined that esketamine, a nasal spray to treat severe depression, is currently too expensive for widespread use. Titled "Cost-Effectiveness of Esketamine Nasal ...

Psychology & Psychiatry

New study shows how ketamine combats depression

In low doses, the anaesthetic drug ketamine has been shown to have a rapid effect on difficult-to-treat depression. Researchers at Karolinska Institutet report that they have identified a key target for the drug: specific ...

Psychology & Psychiatry

Revisiting the potential of using psychedelic drugs in psychiatry

Before they were banned about a half century ago, psychedelic drugs like LSD and psilocybin showed promise for treating conditions including alcoholism and some psychiatric disorders. In a commentary publishing April 2 in ...

page 1 from 4